Hudson Bay Capital Management’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-85,000
| Closed | -$2.01M | – | 947 |
|
|
2023
Q4 | $2.01M | Buy |
85,000
+55,000
| +183% | +$980K | 0.01% | 456 |
|
|
2023
Q3 | $447K | Buy |
+30,000
| New | +$398K | ﹤0.01% | 606 |
|
|
2023
Q2 | – | Sell |
-266,400
| Closed | -$2.32M | – | 1030 |
|
|
2023
Q1 | $2.32M | Sell |
266,400
-431,100
| -62% | -$3.45M | 0.02% | 499 |
|
|
2022
Q4 | $4.37M | Sell |
697,500
-627,500
| -47% | -$2.39M | 0.04% | 389 |
|
|
2022
Q3 | $4.64M | Sell |
1,325,000
-174,900
| -12% | -$628K | 0.04% | 445 |
|
|
2022
Q2 | $4.42M | Buy |
1,499,900
+714,900
| +91% | +$1.71M | 0.03% | 484 |
|
|
2022
Q1 | $2.44M | Buy |
785,000
+135,000
| +21% | +$425K | 0.03% | 657 |
|
|
2021
Q4 | $2.2M | Buy |
650,000
+269,948
| +71% | +$1.02M | 0.02% | 652 |
|
|
2021
Q3 | $1.39M | Buy |
380,052
+80,052
| +27% | +$315K | 0.02% | 697 |
|
|
2021
Q2 | $1.31M | Buy |
300,000
+95,000
| +46% | +$421K | 0.02% | 691 |
|
|
2021
Q1 | $931K | Buy |
205,000
+112,241
| +121% | +$604K | 0.01% | 693 |
|
|
2020
Q4 | $532K | Buy |
+92,759
| New | +$702K | 0.01% | 495 |
|
|
2020
Q3 | – | Sell |
-335,000
| Closed | -$1.17M | – | 656 |
|
|
2020
Q2 | $1.17M | Buy |
335,000
+120,000
| +56% | +$346K | 0.02% | 366 |
|
|
2020
Q1 | $318K | Sell |
215,000
-110,000
| -34% | -$185K | 0.01% | 388 |
|
|
2019
Q4 | $637K | Buy |
+325,000
| New | +$1.22M | 0.01% | 335 |
|
|
2019
Q3 | – | Sell |
-14,000
| Closed | -$100K | – | 496 |
|
|
2019
Q2 | $100K | Buy |
+14,000
| New | +$159K | ﹤0.01% | 384 |
|
Other funds holding CBAY
Hudson Bay Capital Management's CBAY Position: Q1 2024 in Review
Hudson Bay Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 85,000 shares — an estimated $2.01M sold.
Hudson Bay Capital Management first reported a position in CBAY in Q2 2019 and held it in 16 quarters. The position peaked at $4.64M in Q3 2022. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Hudson Bay Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Hudson Bay Capital Management sold 85,000 Cymabay Therapeutics shares in Q1 2024, an estimated $2.01M.
- Hudson Bay Capital Management first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 16 quarters.
- Hudson Bay Capital Management's Cymabay Therapeutics position peaked at $4.64M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Hudson Bay Capital Management's 13F filing for Q1 2024, filed 15 May 2024.